Antibodies targeting programmed cell death-1 (PD-1) and its ligand (PD-L1) are successfully used for treatment in a variety of cancers, including metastatic and inoperable cutaneous squamous cell carcinoma (cSCC). Here, RPL17 is linked to cutaneous squamous cell carcinoma.